Intrasense, a global leader in multi-modal medical imaging software in oncology, participated in ASCO 2014 held in Chicago.
ASCO provides the 25,000 oncology professionals attending the annual meeting with cutting-edge scientific presentations and comprehensive educational content. The congress, with its technical exhibition, is also a very special opportunity for oncologists, investigators, pharma companies and their suppliers to meet and exchange on best-in-class oncology-oriented solutions and products.
Myrian, developed by Intrasense, is the ultimate solution for image-based diagnosis and follow-up in oncology. Myrian platform and its range of clinical modules – including Myrian XL-Onco, Myrian XP-Liver, Myrian XP-Breast, Myrian XP-Prostate, Myrian XP-Colon, Myrian XP-LungNodule and Myrian XT-Brain – allow CROs and hospitals to improve their oncology work-flow for clinical research and patient care and to improve quality of care. Moreover, the solution allows them to benefit from multiparametric and multimodal imaging, qualitative and quantitative information and biomarkers, to standardise imaging assessments for clinical trials through structured reading, to facilitate tumour boards and to enhance reporting and communication.
About Intrasense
Created in 2004 with an innovative technology of tissues detection in CT scan, Intrasense designs, develops and markets Myrian, a unique, vendor-neutral software suite for the visualisation and advanced processing of multimodal medical images such as MRI, CT scans, PET, X-rays, and more. Developed with leading academic and scientific partners, Myrian combines and uses all of the various medical images to extract information vital to the patient’s care, to evaluate treatment efficiency and to assess drug candidates in oncology and other pathologies. With more than 700 client sites around the world, Myrian has been certified as a ‘medical device’ in over 40 countries including the US (FDA), Europe (CE) and Asia. Intrasense SA is listed on the Alternext (FR0011179886 – ALINS). The company employs 70 people, including 25 dedicated in R&D. Labelled ‘innovative company by Oseo, Intrasense has invested more than € 9 million in R&D since its creation.
For more about Intrasense, please visit www.intrasense.net
- Advertisement -
